DE602004016754D1 - Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839 - Google Patents

Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839

Info

Publication number
DE602004016754D1
DE602004016754D1 DE602004016754T DE602004016754T DE602004016754D1 DE 602004016754 D1 DE602004016754 D1 DE 602004016754D1 DE 602004016754 T DE602004016754 T DE 602004016754T DE 602004016754 T DE602004016754 T DE 602004016754T DE 602004016754 D1 DE602004016754 D1 DE 602004016754D1
Authority
DE
Germany
Prior art keywords
azd2171
combination therapy
human
against cancer
therapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004016754T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004016754D1 publication Critical patent/DE602004016754D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
DE602004016754T 2003-07-10 2004-07-08 Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839 Active DE602004016754D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316127.0A GB0316127D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002944 WO2005004872A1 (en) 2003-07-10 2004-07-08 Cancer combination therapy comprising azd2171 and zd1839

Publications (1)

Publication Number Publication Date
DE602004016754D1 true DE602004016754D1 (de) 2008-11-06

Family

ID=27741907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016754T Active DE602004016754D1 (de) 2003-07-10 2004-07-08 Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839

Country Status (24)

Country Link
US (2) US20060167024A1 (de)
EP (1) EP1653964B1 (de)
JP (1) JP2007526888A (de)
KR (1) KR20060033785A (de)
CN (1) CN100415236C (de)
AT (1) ATE409039T1 (de)
AU (1) AU2004255024B2 (de)
BR (1) BRPI0412408A (de)
CA (1) CA2531620C (de)
DE (1) DE602004016754D1 (de)
DK (1) DK1653964T3 (de)
ES (1) ES2313033T3 (de)
GB (1) GB0316127D0 (de)
HK (1) HK1089667A1 (de)
HR (1) HRP20080597T3 (de)
IL (1) IL172683A0 (de)
MX (1) MXPA06000412A (de)
NO (1) NO20056170L (de)
NZ (1) NZ544270A (de)
PL (1) PL1653964T3 (de)
PT (1) PT1653964E (de)
SI (1) SI1653964T1 (de)
WO (1) WO2005004872A1 (de)
ZA (1) ZA200600184B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
EP2113255A1 (de) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
TR200500745T2 (tr) * 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
EP1272200B1 (de) * 2000-03-31 2005-06-22 Angiogene Pharmaceuticals Ltd Getrennte dosis therapien mit gefässschädigender aktivität
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2002041882A2 (en) * 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
RU2362774C1 (ru) * 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения

Also Published As

Publication number Publication date
AU2004255024A1 (en) 2005-01-20
NZ544270A (en) 2007-09-28
JP2007526888A (ja) 2007-09-20
US20060167024A1 (en) 2006-07-27
WO2005004872A1 (en) 2005-01-20
EP1653964A1 (de) 2006-05-10
IL172683A0 (en) 2006-04-10
KR20060033785A (ko) 2006-04-19
CA2531620C (en) 2011-09-27
PL1653964T3 (pl) 2009-01-30
HRP20080597T3 (en) 2008-12-31
US20100179142A1 (en) 2010-07-15
ZA200600184B (en) 2007-04-25
HK1089667A1 (en) 2006-12-08
ATE409039T1 (de) 2008-10-15
CA2531620A1 (en) 2005-01-20
ES2313033T3 (es) 2009-03-01
CN1819831A (zh) 2006-08-16
SI1653964T1 (sl) 2009-02-28
BRPI0412408A (pt) 2006-08-22
CN100415236C (zh) 2008-09-03
EP1653964B1 (de) 2008-09-24
AU2004255024B2 (en) 2007-09-27
DK1653964T3 (da) 2009-01-05
PT1653964E (pt) 2008-11-24
NO20056170L (no) 2006-02-08
MXPA06000412A (es) 2006-03-17
GB0316127D0 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20064755L (no) Kombinasjonsterapi
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
NO20064754L (no) Kombinasjonsterapi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition